259 related articles for article (PubMed ID: 32699136)
21. Inflammasome activation in bovine monocytes by extracellular ATP does not require the purinergic receptor P2X7.
Hussen J; Düvel A; Koy M; Schuberth HJ
Dev Comp Immunol; 2012 Oct; 38(2):312-20. PubMed ID: 22728096
[TBL] [Abstract][Full Text] [Related]
22. NR4A transcription factors limit CAR T cell function in solid tumours.
Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
[TBL] [Abstract][Full Text] [Related]
23. Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.
Draganov D; Gopalakrishna-Pillai S; Chen YR; Zuckerman N; Moeller S; Wang C; Ann D; Lee PP
Sci Rep; 2015 Nov; 5():16222. PubMed ID: 26552848
[TBL] [Abstract][Full Text] [Related]
24. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
[TBL] [Abstract][Full Text] [Related]
25. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
26. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
27. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
28. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.
Zhu J; Powis de Tenbossche CG; Cané S; Colau D; van Baren N; Lurquin C; Schmitt-Verhulst AM; Liljeström P; Uyttenhove C; Van den Eynde BJ
Nat Commun; 2017 Nov; 8(1):1404. PubMed ID: 29123081
[TBL] [Abstract][Full Text] [Related]
29. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
[TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
Garcia-Hernandez Mde L; Hamada H; Reome JB; Misra SK; Tighe MP; Dutton RW
J Immunol; 2010 Apr; 184(8):4215-27. PubMed ID: 20237297
[TBL] [Abstract][Full Text] [Related]
31. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
32. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
Varn FS; Schaafsma E; Wang Y; Cheng C
Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
Milling SW; Sai T; Silvers WK; Mintz B
Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
35. Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.
Jimenez-Pacheco A; Diaz-Hernandez M; Arribas-Blázquez M; Sanz-Rodriguez A; Olivos-Oré LA; Artalejo AR; Alves M; Letavic M; Miras-Portugal MT; Conroy RM; Delanty N; Farrell MA; O'Brien DF; Bhattacharya A; Engel T; Henshall DC
J Neurosci; 2016 Jun; 36(22):5920-32. PubMed ID: 27251615
[TBL] [Abstract][Full Text] [Related]
36. Radiosensitizing Effect of P2X7 Receptor Antagonist on Melanoma in Vitro and in Vivo.
Tanamachi K; Nishino K; Mori N; Suzuki T; Tanuma SI; Abe R; Tsukimoto M
Biol Pharm Bull; 2017 Jun; 40(6):878-887. PubMed ID: 28344198
[TBL] [Abstract][Full Text] [Related]
37. Porphyromonas gingivalis-nucleoside-diphosphate-kinase inhibits ATP-induced reactive-oxygen-species via P2X7 receptor/NADPH-oxidase signalling and contributes to persistence.
Choi CH; Spooner R; DeGuzman J; Koutouzis T; Ojcius DM; Yilmaz Ö
Cell Microbiol; 2013 Jun; 15(6):961-76. PubMed ID: 23241000
[TBL] [Abstract][Full Text] [Related]
38. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
[TBL] [Abstract][Full Text] [Related]
39.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
40. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]